Compare Stocks: ASRT, CTNM, EOLS, and TLRY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$23.50	$23.42	$8.61 ▼ $23.50	$151.81M	0.52	271,083 shs	N/A
CTNM Contineum Therapeutics	$15.14 -5.0%	$15.39	$8.60 ▼ $17.78	$569.57M	0.75	325,268 shs	388,829 shs
EOLS Evolus	$8.57 -3.5%	$7.34	$3.86 ▼ $9.31	$566.05M	1.42	1.04 million shs	996,573 shs
TLRY Tilray Brands	$4.21 -2.1%	$4.46	$3.67 ▼ $23.20	$573.40M	1.92	4.25 million shs	4.95 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	0.00%	0.00%	0.00%	+0.09%	+94.64%
CTNM Contineum Therapeutics	-4.55%	-3.69%	+5.98%	+41.06%	+31.41%
EOLS Evolus	-4.52%	-2.20%	+17.00%	+32.14%	+16.69%
TLRY Tilray Brands	-4.44%	-4.44%	-5.91%	-14.34%	-61.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$23.50	$23.42	$8.61 ▼ $23.50	$151.81M	0.52	271,083 shs	N/A
CTNM Contineum Therapeutics	$15.14 -5.0%	$15.39	$8.60 ▼ $17.78	$569.57M	0.75	325,268 shs	388,829 shs
EOLS Evolus	$8.57 -3.5%	$7.34	$3.86 ▼ $9.31	$566.05M	1.42	1.04 million shs	996,573 shs
TLRY Tilray Brands	$4.21 -2.1%	$4.46	$3.67 ▼ $23.20	$573.40M	1.92	4.25 million shs	4.95 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	0.00%	0.00%	0.00%	+0.09%	+94.64%
CTNM Contineum Therapeutics	-4.55%	-3.69%	+5.98%	+41.06%	+31.41%
EOLS Evolus	-4.52%	-2.20%	+17.00%	+32.14%	+16.69%
TLRY Tilray Brands	-4.44%	-4.44%	-5.91%	-14.34%	-61.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	1.80	Reduce	$22.65	-3.62% Downside
CTNM Contineum Therapeutics	2.40	Hold	$20.25	33.75% Upside
EOLS Evolus	2.50	Moderate Buy	$14.50	69.19% Upside
TLRY Tilray Brands	2.43	Hold	$8.00	90.02% Upside

Current Analyst Ratings Breakdown

Latest ASRT, CTNM, EOLS, and TLRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/24/2026	TLRY Tilray Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	TLRY Tilray Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/31/2026	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
7/31/2026	TLRY Tilray Brands	TD Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	CTNM Contineum Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	TLRY Tilray Brands	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $5.00
6/17/2026	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
6/15/2026	EOLS Evolus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$118.71M	1.28	$0.02 per share	1,437.29	$14.63 per share	1.61
CTNM Contineum Therapeutics	$50M	11.39	N/A	N/A	$6.99 per share	2.17
EOLS Evolus	$297.18M	1.90	N/A	N/A	($0.36) per share	-23.81
TLRY Tilray Brands	$915.45M	0.63	N/A	N/A	$13.68 per share	0.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$30.38M	-$5.69	N/A	21.17	N/A	-34.94%	-38.72%	-13.32%	N/A
CTNM Contineum Therapeutics	-$59.98M	-$1.73	N/A	N/A	N/A	N/A	-24.73%	-23.51%	10/29/2026 (Estimated)
EOLS Evolus	-$51.64M	-$0.52	N/A	107.13	N/A	-10.85%	N/A	-13.00%	11/4/2026 (Estimated)
TLRY Tilray Brands	-$121.40M	-$1.08	N/A	N/A	N/A	-13.11%	-7.76%	-5.59%	10/8/2026 (Estimated)

Latest ASRT, CTNM, EOLS, and TLRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/30/2026	Q2 2026	CTNM Contineum Therapeutics	-$0.4488	-$0.40	+$0.0488	-$0.40	N/A	N/A
7/28/2026	Q4 2026	TLRY Tilray Brands	-$0.0120	-$0.43	-$0.4180	-$0.43	$246.30 million	$281.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.52	1.82	1.57
CTNM Contineum Therapeutics	N/A	37.17	37.17
EOLS Evolus	N/A	1.70	1.28
TLRY Tilray Brands	0.22	2.21	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
CTNM Contineum Therapeutics	N/A
EOLS Evolus	90.69%
TLRY Tilray Brands	9.35%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	5.70%
CTNM Contineum Therapeutics	7.90%
EOLS Evolus	5.00%
TLRY Tilray Brands	0.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	6.46 million	6.09 million	Optionable
CTNM Contineum Therapeutics	31	37.62 million	34.65 million	N/A
EOLS Evolus	170	66.05 million	62.75 million	Optionable
TLRY Tilray Brands	3,595	136.20 million	135.06 million	Optionable

ASRT, CTNM, EOLS, and TLRY Headlines

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY) Stock Price Down 2.1% - Here's What Happened

29 minutes ago | marketbeat.com

Broncos Country, This One’s for You: Breckenridge Distillery Kicks Off Another Season with the Denver Broncos and a Limited-Edition Whiskey Collection Honoring “The Drive”

September 9 at 9:14 AM | finance.yahoo.com

Broncos Country, This One's for You: Breckenridge Distillery Kicks Off Another Season with the Denver Broncos and a Limited-Edition Whiskey Collection Honoring “The Drive”

September 9 at 7:00 AM | globenewswire.com

Why Tilray Brands, Inc. (TLRY) Dipped More Than Broader Market Today

September 8 at 7:00 PM | zacks.com

Why Tilray Brands, Inc. (TLRY) Dipped More Than Broader Market Today

September 8 at 6:12 PM | finance.yahoo.com

Tilray Brands (NASDAQ:TLRY) Trading Down 4.4% - Here's Why

September 8 at 5:39 PM | marketbeat.com

BrewDog Roars into Rugby with Five-Year Leicester Tigers Partnership, Bringing Punk Energy to Welford Road

September 8 at 8:08 AM | finance.yahoo.com

BrewDog Roars into Rugby with Five-Year Leicester Tigers Partnership, Bringing Punk Energy to Welford Road

September 8 at 7:11 AM | financialpost.comF

BlackRock Inc. Acquires New Stake in Tilray Brands, Inc. $TLRY

September 6 at 3:36 AM | marketbeat.com

Breckenridge Distillery and Southern Glazer’s Expand Partnership Across New York and California

September 5, 2026 | finance.yahoo.com

Breckenridge Distillery and Southern Glazer’s Expand Partnership Across New York and California

September 3, 2026 | uk.finance.yahoo.com

Promising Cannabis Stocks To Follow Today - September 3rd

September 3, 2026 | marketbeat.com

Tilray Brands' Breckenridge Distillery Expands Distribution in New York, California

September 3, 2026 | finance.yahoo.com

Breckenridge Distillery and Southern Glazer's Expand Partnership Across New York and California

September 3, 2026 | globenewswire.com

Tilray's Rescheduling Rally Keeps Fading -- Where Will the Stock Be if Washington Stalls Again?

September 2, 2026 | fool.com

Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands?

September 2, 2026 | fool.com

Promising Cannabis Stocks To Watch Now - September 2nd

September 2, 2026 | marketbeat.com

September 2, 2026 | globenewswire.com

Tilray Brands, Inc. (NASDAQ:TLRY) Given Consensus Rating of "Hold" by Brokerages

September 2, 2026 | americanbankingnews.com

Tilray Brands, Inc. (NASDAQ:TLRY) Receives Consensus Rating of "Hold" from Analysts

September 2, 2026 | marketbeat.com

Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors

September 1, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, CTNM, EOLS, and TLRY Company Descriptions

Assertio NASDAQ:ASRT

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Contineum Therapeutics NASDAQ:CTNM

$15.14 -0.80 (-5.02%)

Closing price 04:00 PM Eastern

Extended Trading

$15.14 +0.00 (+0.03%)

As of 04:43 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Evolus NASDAQ:EOLS

$8.57 -0.31 (-3.49%)

Closing price 04:00 PM Eastern

Extended Trading

$8.56 -0.01 (-0.12%)

As of 04:10 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Tilray Brands NASDAQ:TLRY

$4.21 -0.09 (-2.09%)

Closing price 04:00 PM Eastern

Extended Trading

$4.21 0.00 (0.00%)

As of 06:08 PM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASRT, CTNM, EOLS, and TLRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASRT, CTNM, EOLS, and TLRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASRT, CTNM, EOLS, and TLRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, CTNM, EOLS, and TLRY Company Descriptions

Assertio NASDAQ:ASRT

Contineum Therapeutics NASDAQ:CTNM

Evolus NASDAQ:EOLS

Tilray Brands NASDAQ:TLRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASRT, CTNM, EOLS, and TLRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASRT, CTNM, EOLS, and TLRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASRT, CTNM, EOLS, and TLRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, CTNM, EOLS, and TLRY Company Descriptions

Assertio NASDAQ:ASRT

Contineum Therapeutics NASDAQ:CTNM

Evolus NASDAQ:EOLS

Tilray Brands NASDAQ:TLRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools